NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 165 filers reported holding NOVOCURE LTD in Q2 2018. The put-call ratio across all filers is 0.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $401,000 | -90.9% | 3,600 | -93.9% | 0.12% | -68.9% |
Q3 2019 | $4,414,000 | +34.7% | 59,024 | +13.9% | 0.38% | +47.9% |
Q2 2019 | $3,277,000 | +30.2% | 51,824 | -35.6% | 0.26% | +41.2% |
Q2 2018 | $2,517,000 | -16.7% | 80,423 | -42.0% | 0.18% | -19.8% |
Q1 2018 | $3,022,000 | – | 138,620 | – | 0.23% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |